According to the needs of the business development of Wuhan Yuanda Pharmaceutical Group, the company has newly established a wholly-owned subsidiary "Wuhan Yuanda Pharmaceutical Group Sales Co., Ltd." (hereinafter referred to as "Sales Co., Ltd."). The business scope of the sales company is: Chinese patent medicines, chemical raw materials, chemical pharmaceutical preparations, antibiotic preparations and biochemical drugs. The legal representative of the sales company is Xie Guofan, and the general manager is Shi Xiaofeng.
all the personnel and business of the original "sales branch of Wuhan Yuanda Pharmaceutical Group Co., Ltd." (hereinafter referred to as "sales branch") were transferred to sales co., Ltd. from January 1, 211. After more than 6 years of development, Wuhan Yuanda Pharmaceutical Co., Ltd. has become a modern Sino-foreign joint venture pharmaceutical enterprise with a registered capital of 85 million yuan, covering an area of 3 mu and a construction area of 96, square meters. The company is mainly engaged in pharmaceutical preparations, pharmaceutical raw materials and intermediates, with an annual sales income of 4 million yuan and an annual export income of 15 million US dollars. It has the annual production capacity of 2 million liquid preparations, more than 4 billion solid preparations and more than 4, tons of raw materials, and is a designated enterprise for national combat readiness reserves of first-aid drugs and narcotics.
The company mainly deals in pharmaceutical raw materials, intermediates and pharmaceutical preparations. It mainly produces more than 3 kinds of raw materials and intermediates, such as metamizole, metronidazole, enoxacin, pirocin sodium, tiopronin and norrenin, among which norrenin has passed the FDA certification. The company has independently developed 3 national second-class new drugs and 9 national fourth-class new drugs, taking the lead in introducing the national cardiovascular new drug Hinweining (tirofiban hydrochloride and sodium chloride injection). Now, the company has formed new and special product groups, such as antibacterial drugs with Nuojia series as the core, cardiovascular drugs with Xinweining as the core, drugs for liver diseases with Nuoning as the core, and ophthalmic drugs with Baineton and Jingming as the core, and has become the key "high-tech enterprise" of the Torch Program of the Ministry of Science and Technology. Wuhan Yuanda Pharmaceutical Group Sales Branch is the sales platform of China Yuanda Pharmaceutical Division, which is responsible for promoting the professional pharmaceutical products of its enterprises. Wuhan Tiantianming Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Yuanda Pharmaceutical Group. Founded in 1996, it is a national key ophthalmic drug production base and a high-tech enterprise supported by the state. Wuhan Yuanda Sales Branch is a professional sales company focusing on ophthalmology and cardiovascular products under Wuhan Yuanda Pharmaceutical Group! The company has a strong and competitive professional sales team, and its marketing network covers the whole country, with offices in all provinces, cities and autonomous regions except Taiwan Province. The company's product line is extensive and far-reaching, with new and special product groups with Bai Neiting, Nuojia, Tiantianming series and cardiovascular product line as the core. There are 6 national second-class new drugs, 11 fourth-class new drugs, 8 new products to be listed soon and 16 varieties under research. Only ENT products contain 22 varieties in 5 categories, and the products are unique.
Among them, Bai Neiting series, a famous brand product, has created a classic in the history of cataract medication, which has gone down in history and lasted for a long time. It has exclusive trademark naming rights and won many provincial silver medals. In 23, the new products Bingzhen Qingmu and Bingzhen Qumao Eye Drops were approved by the word "Zhun", and they entered the list of over-the-counter drugs (OTC Chinese medicine preparations), which were deeply recognized by consumers.
in p>24, a new internationally advanced platelet membrane glycoprotein GPⅡb/Ⅲa receptor antagonist "xinweining" (tirofiban hydrochloride and sodium chloride injection) was officially launched, which filled the gap of domestic antiplatelet preparations. In March 21, Wuhan Yuanda wholly acquired Hubei Ruizhu Pharmaceutical
Wuhan Yuanda Pharmaceutical Group Sales Branch is the sales platform of China Yuanda Pharmaceutical Division, which is responsible for promoting the professional pharmaceutical products of its enterprises. Wuhan Tiantianming Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Wuhan Yuanda Pharmaceutical Group. Founded in 1996, it is a national key ophthalmic drug production base and a high-tech enterprise supported by the state. In 21, Wuhan Yuanda wholly acquired Hubei Ruizhu Pharmaceutical Co., Ltd., which owned the eye gel production line of Italian AXOMATIC Company and the "three-in-one" eye drop production line of American WEILER Company, both of which were world-class production equipment, mainly producing eye gel and preservative-free daily dosage eye drops. After the merger, Wuhan Yuanda Tiantianming Pharmaceutical Company has always regarded seizing the commanding heights of science and technology as the foundation of enterprise development. In order to ensure the forward-looking technology, it has established a rapid and virtuous cycle of scientific and technological innovation system from research to development and production.
based on the principle of saving the world, Wuhan Yuanda firmly believes that the greater the ability, the heavier the responsibility. Every day, it will measure the world with its feet, and the pace under its feet will be firmer and faster, making constant contributions to the bright cause and health cause of all mankind!